^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Non Small Cell Lung Cancer
    Drug:glecirasib (JAB-21822) (KRAS G12C inhibitor) +
    JAB-3312 (PTPN11 inhibitor, MAPK inhibitor, KRAS inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

    Excerpt:
    ...- Subjects with histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors who have failed or lack standard-of-care (SOC) or are unwilling to undergo or intolerant to SOC; those with solid tumors harboring KRAS p.G12C mutation are preferred;...
    Trial ID:
    NCT05288205
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    653O - Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors

    Published date:
    10/16/2023
    Excerpt:
    Out of 28 evaluable pts with KRAS G12Ci naïve NSCLC, ORR was 50% (14/28) and DCR was 100%. In pts with KRAS G12Ci treated NSCLC, ORR was 14.3% (1/7), and DCR was 57.1%...Glecirasib plus JAB-3312 was well tolerated with promising efficacy in KRAS p.G12C NSCLC.
    Trial ID:
    NCT05288205